Rituximab antibody | MB2A4

100% Secure


Rat anti Rituximab:FITC

Rat anti-rituximab antibody, clone MB2A4, recognizes the monoclonal antibody rituximab, which targets CD20. This anti-rituximab antibody is highly specific and ideal for bioanalytical assay development (PK, PD, ADA assays) in preclinical R&D and clinical trials.

Rat anti Rituximab:HRP

Rat anti-rituximab antibody, clone MB2A4, recognizes the monoclonal antibody rituximab, which targets CD20. This anti-rituximab antibody is highly specific and ideal for bioanalytical assay development (PK, PD, ADA assays) in preclinical R&D and clinical trials.

Rat anti Rituximab

Rat anti-rituximab antibody, clone MB2A4, recognizes the monoclonal antibody rituximab, which targets CD20. This anti-rituximab antibody is highly specific and ideal for bioanalytical assay development (PK, PD, ADA assays) in preclinical R&D and clinical trials.

Product Type
Monoclonal Antibody
Clone
MB2A4
Isotype
IgG2a
Product Code Applications Pack Size List Price Quantity
MCA2260F
Datasheet
F
MSDS
0.1 mg loader

MCA2260P
Datasheet
E
MSDS
0.1 mg loader

MCA2260
Datasheet
E F
MSDS
0.2 mg loader

MCA2260G
Datasheet
E F
MSDS
2 mg loader

Rat Anti-Rituximab Antibody, clone MB2A4, is an anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug rituximab. The antibody can be used to measure the levels of rituximab and biosimilar products in bioanalytical assays. Rat Anti-Rituximab Antibody, clone MB2A4, is specific for rituximab and does not recognize other CD20 antibodies. Clone MB2A4 has been used in ELISA to monitor the levels of rituximab in patient serum following therapy (Cragg et al. 2004 and Hampson et al. 2010).

Clone MB2A4 has been used to detect rituximab bound to the surface of the Raji B cell line, however detection of rituximab bound in vivo to B-CLL cells has not been demonstrated. It is possible that complement deposition on rituximab opsonised cells inhibits binding of the Anti-Rituximab Antibody to cell bound rituximab (Beum et al. 2004). Inhibition experiments carried out with Daudi cells demonstrated that this antibody is inhibitory at a ratio of 5:1 antibody:rituximab, but does not inhibit rituximab binding to CD20 at a ratio of 1:1.

Rituximab (reference product branded as Rituxan) is a chimeric mouse/human monoclonal antibody approved for the treatment of certain autoimmune diseases and cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. The antibody is specific for the cell surface protein CD20, which is widely expressed on B cells. Through three different mechanisms of action it eliminates B cells from the body, enabling the development of a new population of healthy B cells.

View a summary of all Anti-Rituximab Antibodies.

Product Details

Product Form
Purified IgG - liquid
Product Form
Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid
Product Form
Purified IgG - liquid
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
TRIS buffered saline
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.01% Thiomersal
HRP Stabiliser (BUF052A)
Preservative Stabilisers
Pack Size: 0.2 mg
0.09% Sodium Azide (NaN3)
Pack Size: 2 mg
0.09% Sodium Azide (NaN3)
Immunogen
F(ab)2 fragment of Rituximab
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Fusion Partners
Spleen cells from immunised rats were fused with cells of the NS-1 mouse myeloma cell line

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted.
Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee
18 months from date of despatch.
Guarantee
18 months from date of despatch.
Guarantee
18 months from date of despatch

More Information

Acknowledgements
Rituxan® is a registered trademark of Biogen Idec/Genentech in the USA.
MabThera ® is a registered trademark of Roche in Europe.
Acknowledgements
Rituxan® is a registered trademark of Biogen Idec/Genentech in the USA.
MabThera ® is a registered trademark of Roche in Europe
Acknowledgements
Rituxan is a registered trademark of Biogen Idec/Genentech in the USA.
MabThera is a registered trademark of Roche in Europe.
Regulatory
For research purposes only

Applications of Rituximab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat
ELISA 1/20000 1/200000
ELISA
Flow Cytometry 50 ug/ml
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
ELISA
This product may be used in a direct ELISA or as a detection reagent in a sandwich ELISA together with HCA186 as the capture reagent. Protocol: PK bridging ELISA to measure free drug
ELISA
This product may be used in a direct ELISA or as a detection reagent, when conjugated to HRP, in a sandwich ELISA together with HCA186 as the capture reagent. Protocol: PK bridging ELISA to measure free drug

Secondary Antibodies Available

Description Product Code Applications Pack Size List Price Quantity
Rabbit F(ab')2 anti Rat IgG:FITC STAR17B F 1 mg loader
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) STAR69 F 0.5 ml loader
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) STAR73 F 0.5 ml loader

Useful Reagents Available

Description Product Code Applications Pack Size List Price Quantity
Human anti Rituximab HCA061 E 0.1 mg loader
Human anti Rituximab:HRP HCA061P E 0.1 mg loader
Human anti Rituximab HCA062 E 0.1 mg loader
Human anti Rituximab:HRP HCA062P E 0.1 mg loader
Human anti Rituximab HCA186 E 0.1 mg loader
Human anti Rituximab HCA061 E 0.1 mg loader
Human anti Rituximab:HRP HCA061P E 0.1 mg loader
Human anti Rituximab HCA062 E 0.1 mg loader
Human anti Rituximab:HRP HCA062P E 0.1 mg loader
Human anti Rituximab HCA186 E 0.1 mg loader
Human anti Rituximab HCA061 E 0.1 mg loader
Human anti Rituximab:HRP HCA061P E 0.1 mg loader
Human anti Rituximab HCA062 E 0.1 mg loader
Human anti Rituximab:HRP HCA062P E 0.1 mg loader
Human anti Rituximab HCA186 E 0.1 mg loader

Application Based External Images

Flow Cytometry

Western Blotting

Product Specific References

References for Rituximab antibody

  1. Cragg, M. S. et al. (2004) A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells.
    Blood. 104:2540-2
  2. Cragg, M.S. et al. (2004) Apparent modulation of CD20 by rituximab: an alternative explanation.
    Blood. 103 (10): 3989-90; author reply 3990-1.
  3. Beum, P.V. et al. (2004) Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.
    J Immunol Methods. 294 (1-2): 37-42.
  4. Hampson, G. et al. (2010) Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects.
    J Immunol Methods. 360 (1-2): 30-8.
  5. Blasco, H. et al. (2007) Evaluation of a peptide ELISA for the detection of rituximab in serum.
    J Immunol Methods.325: 127-39.
  6. Daydé, D. et al. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.
    Blood. 113: 3765-72.
  7. Aung, T. et al. (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.
    Proc Natl Acad Sci U S A. 108: 15336-41.
  8. Schmidt, E. et al. (2009) Immunogenicity of rituximab in patients with severe pemphigus.
    Clin Immunol. 132: 334-41.
  9. McDonald, V. et al. (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.
    J Thromb Haemost. 8: 1201-8.
  10. Kagan, L. et al. (2012) Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats.
    Pharm Res. 29: 490-499
  11. Kagan, L. and Mager, D.E. (2013) Mechanisms of subcutaneous absorption of rituximab in rats.
    Drug Metab Dispos. 41: 248-55.
  12. Liu, X.F. et al. (2012) Validation of a Gyrolab™ assay for quantification of rituximab in human serum.
    J Pharmacol Toxicol Methods. 65: 107-14.
  13. Kagan, L. et al. (2014) Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats.
    Pharm Res. 31: 3265-73.
  14. Blasco, H. et al. (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma.
    Fundam Clin Pharmacol. 23: 601-8.
  15. Pers, J.O. et al. (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Arthritis Rheum. 56: 1464-77.
  16. Vacher, P. et al. (2015) Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas.
    J Immunol. pii: 1402942.
  17. Komori, M. et al. (2016) Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
    Annals of Clinical and Translational Neurology. Feb 1. [Epub ahead of print]
  18. Illidge, T.M. et al. (2016) Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
    Br J Haematol. Feb 5. [Epub ahead of print]
  19. Lioger, B. et al. (2017) Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.
    Br J Clin Pharmacol. Feb 23. [Epub ahead of print]
  20. Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
    US Patent Application US20170315118A1